Abbott Introduces Tool to Identify Heart & Kidney Risk in Diabetes

Abbott has also announced the introduction of the International Cardio-Renal Risk Assessment and Stratification (ICRAS) Tool, a web-based tool that is designed to assist physicians in India in diagnosing the risks of heart and kidneys in individuals with type 2 diabetes mellitus (T2DM)

India is also known as the diabetes capital of the world as almost 101 million individuals are living with diabetes. CVDs and KDs are still one of the most frequent and severe complications of type 2 diabetes, and the timely detection of cardio-renal risks is becoming a more significant issue for clinicians and the healthcare sector

The company says that the tool will help clinicians evaluate cardio-renal risk at an early stage of individuals with T2DM to deliver better patient outcomes and prevent complications related to the disease.

Also Read: How to Bridge the Healthcare Gap in Emerging Markets with MedTech

Dr. Kartik Peethambaran, Medical Director, Abbott India, said, “We continue to partner with healthcare professionals to support appropriate patient screening and improve clinical outcomes. The ICRAS tool is designed to help clinicians assess a diabetic patient’s likelihood of developing diabetic kidney disease (DKD), coronary heart disease (CHD), and major adverse cardiovascular events (MACE).”

ICRAS Tool is a combination of essential health indicators such as medical test results and lifestyle factors to produce independent risk scores of kidney disease, heart disease and major cardiac events. It also takes into account the differences in risk by gender and fails to record any personal data about the patient or physician, which guarantees the privacy and safe clinical evaluations.